RTW Investments and Roderick Wong Acquire 8.8% Stake in Candel Therapeutics (CADL)

On May 15, 2026, RTW Investments, LP and Roderick Wong, M.D. filed a Schedule 13G with the SEC, disclosing a new 8.8% ownership stake in Candel Therapeutics, Inc. (CADL). The reporting persons beneficially own 6,422,018 shares of common stock as of the event date on March 31, 2026. RTW Investments, LP, a Delaware limited partnership acting as an investment adviser, and Dr. Wong, its Managing Partner and Chief Investment Officer, share voting and dispositive power over these shares. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This position represents a significant new holding for RTW Investments in the biopharmaceutical company, which is based in Needham, Massachusetts. The ownership percentage is calculated based on approximately 73.2 million shares outstanding as reported in the company's recent annual report.